← Research library

ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.

Randomized study in people · 2017

What was studied
503 patients aged 60 or older after ischemic stroke; ARTEMIDA
Main finding
The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.

ADAS-cog+ change at month 6 · −6.8 Actovegin versus −4.6 placebo

Reported findings and study design

ARTEMIDA: 503 patients age ≥60, MoCA≤25, randomized within one week of stroke: Actovegin 248 versus placebo 255. Up to twenty IV infusions 2,000 mg/day, then oral 1,200 mg/day for six months; follow-up 12 months.

Population or model 503 patients aged 60 or older after ischemic stroke; ARTEMIDA

Dose, route and schedule

Actovegin: 2,000 mg/day for up to 20 intravenous infusions, followed by 1,200 mg/day orally, for six months of treatment in total. Treatment began within one week of ischemic stroke.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
ADAS-cog+ change at month 6−6.8 Actovegin versus −4.6 placebo
Estimated treatment difference−2.3 points; 95% CI −3.9 to −0.7p=0.005
Recurrent ischemic strokeMore frequent with Actovegin, not statistically significantEvent counts absent from abstract

Adjusted treatment difference is retained as −2.3 rather than replacing it with subtraction of the rounded means.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Clinical importance and replication remain unresolved. The safety imbalance cannot establish causation or be dismissed as proof of safety. Disease-specific results do not establish healthy-person enhancement.

Source details

Journal publication

Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.

Sources checked

Citation

Randomized trialEnglish abstract

Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke

Study source ↗ · DOI 10.1161/strokeaha.116.014321 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards